NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
86.04
-0.30 (-0.35%)
At close: 4:02PM EDT

86.04 -0.04 (-0.05%)
After hours: 4:05PM EDT

Stock chart is not supported by your current browser
Previous Close86.34
Open86.12
Bid0.00 x 0
Ask0.00 x 0
Day's Range85.88 - 86.31
52 Week Range66.93 - 86.90
Volume1,120,561
Avg. Volume1,556,623
Market Cap200.13B
Beta0.74
PE Ratio (TTM)31.41
EPS (TTM)2.74
Earnings DateN/A
Forward Dividend & Yield2.72 (3.16%)
Ex-Dividend Date2017-03-01
1y Target Est88.67
Trade prices are not sourced from all markets
  • Training cells to fight cancer
    CNBC Videos19 days ago

    Training cells to fight cancer

    In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.

  • Historic treatment, historic price
    CNBC Videos20 days ago

    Historic treatment, historic price

    Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i...

  • The Wall Street Journal19 minutes ago

    Gilead Gets FDA Approval for New Cancer Therapy

    Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.

  • Reuters55 minutes ago

    U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

    U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.

  • Forbes2 hours ago

    FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy

    The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks5 hours ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • What's in the Cards for Novartis (NVS) This Earnings Season?
    Zacks15 hours ago

    What's in the Cards for Novartis (NVS) This Earnings Season?

    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

  • Market Realistyesterday

    Inside Novartis’s Performance in 3Q17

    NVS stock rose ~2.8% in 3Q17 and has risen 18.7% YTD (year-to-date) as of October 16.

  • Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
    Zacksyesterday

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

  • American City Business Journals2 days ago

    Drugmaker Novartis to close 450-employee Sandoz plant in Broomfield

    Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result. The Sandoz facility has been in Broomfield for 42 years. Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said.

  • Let's Talk About CAR-T
    GuruFocus.com2 days ago

    Let's Talk About CAR-T

    A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market

  • Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
    Investor's Business Daily3 days ago

    Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field

    Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace6 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • Reuters7 days ago

    Novartis decides not to sell Roche stake chairman tells newspaper

    Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung. "We said we would review whether it makes sense to sell the stake," Reinhardt told the newspaper. In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks.

  • Forbes8 days ago

    Here Come More Gene Therapies -- And More Pricing Debates

    Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.

  • 4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
    Zacks13 days ago

    4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

    The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

  • Market Realist13 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
    Zacks15 days ago

    FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

    Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

  • CNW Group15 days ago

    IIROC Trade Resumption - NVS

    IIROC Trade Resumption - NVS

  • PR Newswire15 days ago

    IIROC Trade Resumption - NVS

    VANCOUVER , Oct. 3, 2017 /CNW/ - Trading resumes in: Company: Novicius Corp. CSE Symbol: NVS Resumption (ET): 9:30 am IIROC can make a decision to impose a temporary suspension (halt) of trading in a security ...

  • Barrons.com16 days ago

    [$$] Lilly Faces Off With Pfizer, Novartis

    Credit Suisse Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy. Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly. Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease.

  • CNBC19 days ago

    Two patients show the promise of a historic treatment, with an equally historic price tag

    Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.

  • Ligand's Captisol Deals Set to Drive Growth in the Long Run
    Zacks19 days ago

    Ligand's Captisol Deals Set to Drive Growth in the Long Run

    Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.

  • Forbes20 days ago

    Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet

    Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model.

  • Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'
    Investor's Business Daily20 days ago

    Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'

    Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.